Inhibikase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share

Net Loss Per Share

9 Months Ended

Sep. 30, 2021

The following table presents the calculation of basic and diluted net loss per share applicable to common stockholders:


	Nine Months Ended September 30,
	2021			2020
Numerator:
Net loss	$	(9,744,444	)	$	(1,639,908	)
Denominator:
Weighted-average number of common shares outstanding – basic and diluted		15,868,421			8,187,517
Net loss per share applicable to common stockholders – basic and diluted	$	(0.61	)	$	(0.20	)

The following shares were excluded from the calculation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock method, because their effect would have been anti-dilutive for the periods presented:


	Nine Months Ended September 30,
	2021		2020
Options to purchase shares of stock		3,630,044		3,369,144
Warrants to purchase shares of stock		1,561,913		650,948
Total		5,191,957		4,020,092